Drug Of Abuse Testing Services Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Drug Class (Alcohol, Cannabis/Marijuana, Cocaine, Opioids, Amphetamine & Methamphetamine, LSD, Others), By Region & Competition, 2021-2031F

January 2026 | 180 pages | ID: D5F0390E7A8AEN
TechSci Research

Abstracts

The Global Drug Of Abuse Testing Services Market is projected to expand from USD 5.39 Billion in 2025 to USD 7.46 Billion by 2031, reflecting a CAGR of 5.57%. These services involve the detection and analysis of misused prescription medications or illicit substances in biological specimens such as urine, blood, oral fluid, or hair. The market is fundamentally underpinned by strict government regulations requiring safety in high-risk sectors, a growing corporate focus on preventing workplace accidents, and the necessity to minimize liability linked to impaired employee performance. For instance, during the 2024 International Roadcheck, the Commercial Vehicle Safety Alliance reported that inspectors placed 63 commercial drivers out of service due to prohibited status in the federal Drug & Alcohol Clearinghouse, highlighting the critical role of rigorous testing programs in ensuring operational safety and regulatory compliance.

However, the market faces a significant obstacle due to the increasingly intricate legal environment surrounding cannabis legalization. As various jurisdictions implement differing statutes protecting medical or recreational marijuana use, multinational organizations encounter substantial difficulties in establishing standardized testing protocols that align with both evolving employee privacy rights and safety mandates.

Market Driver

A primary catalyst for market growth is the implementation of stringent workplace drug screening mandates, driven by the need to maintain operational safety and mitigate liability risks. Organizations are strengthening protocols to identify impairment that could lead to accidents, especially within the logistics and transportation sectors. According to Quest Diagnostics' 'Annual Drug Testing Index' from May 2024, the overall drug positivity rate in the U.S. workforce remained at 4.6% in 2023. This sustained elevation necessitates continuous monitoring, a fact further supported by Federal Motor Carrier Safety Administration data from May 2024, which showed approximately 176,000 commercial drivers remained in prohibited status within the Drug and Alcohol Clearinghouse, underscoring the reliance on professional testing services to filter disqualified personnel.

Furthermore, the rising global prevalence of illicit substance consumption expands the demand for toxicology analysis across legal and clinical sectors. As substance use disorders increase, institutions require comprehensive screening panels to enforce sobriety orders and manage treatment plans. The United Nations Office on Drugs and Crime reported in the 'World Drug Report 2024' (June 2024) that the number of people using drugs globally rose to 292 million in 2022, a 20% increase over the previous decade. This demographic expansion correlates with higher volumes of biological samples processed for opioids, cannabis, and amphetamines, compelling service providers to scale laboratory capabilities to handle the influx of screening requests from law enforcement and medical interventions.

Market Challenge

The increasingly complex legal landscape regarding cannabis legalization presents a direct threat to the growth of the Drug of Abuse Testing Services Market. With various states legalizing medical or recreational marijuana while federal prohibitions persist, employers face a significant compliance dilemma that hinders the implementation of uniform testing protocols. This regulatory fragmentation creates liability risks, leading many organizations to eliminate cannabis testing or relax their screening criteria to avoid litigation and widen their hiring pools. Consequently, the demand for comprehensive testing panels is negatively impacted, reducing the revenue potential for service providers.

This trend is particularly evident in safety-sensitive industries where workforce retention is crucial, yet federal mandates conflict with state laws. According to the American Trucking Associations, the trucking sector struggled with a persistent driver shortage of 60,000 positions in 2024, a deficit exacerbated by strict testing mandates that disqualify numerous candidates. This labor scarcity forces companies to reconsider the scope of their drug screening programs, thereby stifling the expansion of testing services as the pool of eligible employees shrinks and organizations pivot away from rigorous enforcement to maintain operational levels.

Market Trends

The shift toward oral fluid testing is fundamentally reshaping the market, driven by rising demand for non-invasive, recent-use detection methods and recent federal approvals for regulated sectors. This methodology accelerates integration into corporate screening programs by minimizing sample tampering risks associated with traditional urine collection and mitigating privacy concerns. The efficiency of oral fluid testing is causing a rapid displacement of legacy protocols as organizations seek flexible compliance solutions. According to First Advantage's '2024 Annual Trends Report' (August 2024), the utilization of oral fluid-based screens increased by 74% over the preceding two years, capturing 30% of their total drug screening volume, reflecting a decisive market pivot toward modalities that streamline logistics while maintaining safety standards.

Simultaneously, the expansion of multi-panel screening for synthetic opioids is becoming imperative as the illicit drug supply evolves with dangerous adulterants like fentanyl analogs and xylazine. Standard screening panels are increasingly insufficient, prompting laboratories to develop specialized assays capable of identifying complex poly-substance usage often missed by basic tests. This trend responds to the rising toxicity of drug mixtures, which requires precise toxicological analysis for safety and medical interventions. According to Millennium Health's 'Signals Alert: Xylazine' (July 2024), 16% of fentanyl-positive specimens nationally contained xylazine, with regional positivity rates reaching approximately 40%. Consequently, service providers are rapidly scaling test menus to include these synthetic compounds, ensuring workplace safety programs remain effective against emerging pharmacological threats.

Key Market Players

• Quest Diagnostics
• LabCorp
• Abbott
• Thermo Fisher Scientific
• Siemens Healthineers
• OraSure Technologies
• Huer Diagnostics
• Kindred Biosciences
• Eurofins Scientific
• BioReference Laboratories

Report Scope

In this report, the Global Drug Of Abuse Testing Services Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Drug Of Abuse Testing Services Market, By Drug Class
• Alcohol
• Cannabis/Marijuana
• Cocaine
• Opioids
• Amphetamine & Methamphetamine
• LSD
• Others
• Drug Of Abuse Testing Services Market, By Region
• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Drug Of Abuse Testing Services Market.

Available Customizations:

Global Drug Of Abuse Testing Services Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Contents

1. PRODUCT OVERVIEW

1.1. Market Definition
1.2. Scope of the Market
  1.2.1. Markets Covered
  1.2.2. Years Considered for Study
  1.2.3. Key Market Segmentations

2. RESEARCH METHODOLOGY

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. EXECUTIVE SUMMARY

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. VOICE OF CUSTOMER

5. GLOBAL DRUG OF ABUSE TESTING SERVICES MARKET OUTLOOK

5.1. Market Size & Forecast
  5.1.1. By Value
5.2. Market Share & Forecast
  5.2.1. By Drug Class (Alcohol, Cannabis/Marijuana, Cocaine, Opioids, Amphetamine & Methamphetamine, LSD, Others)
  5.2.2. By Region
  5.2.3. By Company (2025)
5.3. Market Map

6. NORTH AMERICA DRUG OF ABUSE TESTING SERVICES MARKET OUTLOOK

6.1. Market Size & Forecast
  6.1.1. By Value
6.2. Market Share & Forecast
  6.2.1. By Drug Class
  6.2.2. By Country
6.3. North America: Country Analysis
  6.3.1. United States Drug Of Abuse Testing Services Market Outlook
    6.3.1.1. Market Size & Forecast
      6.3.1.1.1. By Value
    6.3.1.2. Market Share & Forecast
      6.3.1.2.1. By Drug Class
  6.3.2. Canada Drug Of Abuse Testing Services Market Outlook
    6.3.2.1. Market Size & Forecast
      6.3.2.1.1. By Value
    6.3.2.2. Market Share & Forecast
      6.3.2.2.1. By Drug Class
  6.3.3. Mexico Drug Of Abuse Testing Services Market Outlook
    6.3.3.1. Market Size & Forecast
      6.3.3.1.1. By Value
    6.3.3.2. Market Share & Forecast
      6.3.3.2.1. By Drug Class

7. EUROPE DRUG OF ABUSE TESTING SERVICES MARKET OUTLOOK

7.1. Market Size & Forecast
  7.1.1. By Value
7.2. Market Share & Forecast
  7.2.1. By Drug Class
  7.2.2. By Country
7.3. Europe: Country Analysis
  7.3.1. Germany Drug Of Abuse Testing Services Market Outlook
    7.3.1.1. Market Size & Forecast
      7.3.1.1.1. By Value
    7.3.1.2. Market Share & Forecast
      7.3.1.2.1. By Drug Class
  7.3.2. France Drug Of Abuse Testing Services Market Outlook
    7.3.2.1. Market Size & Forecast
      7.3.2.1.1. By Value
    7.3.2.2. Market Share & Forecast
      7.3.2.2.1. By Drug Class
  7.3.3. United Kingdom Drug Of Abuse Testing Services Market Outlook
    7.3.3.1. Market Size & Forecast
      7.3.3.1.1. By Value
    7.3.3.2. Market Share & Forecast
      7.3.3.2.1. By Drug Class
  7.3.4. Italy Drug Of Abuse Testing Services Market Outlook
    7.3.4.1. Market Size & Forecast
      7.3.4.1.1. By Value
    7.3.4.2. Market Share & Forecast
      7.3.4.2.1. By Drug Class
  7.3.5. Spain Drug Of Abuse Testing Services Market Outlook
    7.3.5.1. Market Size & Forecast
      7.3.5.1.1. By Value
    7.3.5.2. Market Share & Forecast
      7.3.5.2.1. By Drug Class

8. ASIA PACIFIC DRUG OF ABUSE TESTING SERVICES MARKET OUTLOOK

8.1. Market Size & Forecast
  8.1.1. By Value
8.2. Market Share & Forecast
  8.2.1. By Drug Class
  8.2.2. By Country
8.3. Asia Pacific: Country Analysis
  8.3.1. China Drug Of Abuse Testing Services Market Outlook
    8.3.1.1. Market Size & Forecast
      8.3.1.1.1. By Value
    8.3.1.2. Market Share & Forecast
      8.3.1.2.1. By Drug Class
  8.3.2. India Drug Of Abuse Testing Services Market Outlook
    8.3.2.1. Market Size & Forecast
      8.3.2.1.1. By Value
    8.3.2.2. Market Share & Forecast
      8.3.2.2.1. By Drug Class
  8.3.3. Japan Drug Of Abuse Testing Services Market Outlook
    8.3.3.1. Market Size & Forecast
      8.3.3.1.1. By Value
    8.3.3.2. Market Share & Forecast
      8.3.3.2.1. By Drug Class
  8.3.4. South Korea Drug Of Abuse Testing Services Market Outlook
    8.3.4.1. Market Size & Forecast
      8.3.4.1.1. By Value
    8.3.4.2. Market Share & Forecast
      8.3.4.2.1. By Drug Class
  8.3.5. Australia Drug Of Abuse Testing Services Market Outlook
    8.3.5.1. Market Size & Forecast
      8.3.5.1.1. By Value
    8.3.5.2. Market Share & Forecast
      8.3.5.2.1. By Drug Class

9. MIDDLE EAST & AFRICA DRUG OF ABUSE TESTING SERVICES MARKET OUTLOOK

9.1. Market Size & Forecast
  9.1.1. By Value
9.2. Market Share & Forecast
  9.2.1. By Drug Class
  9.2.2. By Country
9.3. Middle East & Africa: Country Analysis
  9.3.1. Saudi Arabia Drug Of Abuse Testing Services Market Outlook
    9.3.1.1. Market Size & Forecast
      9.3.1.1.1. By Value
    9.3.1.2. Market Share & Forecast
      9.3.1.2.1. By Drug Class
  9.3.2. UAE Drug Of Abuse Testing Services Market Outlook
    9.3.2.1. Market Size & Forecast
      9.3.2.1.1. By Value
    9.3.2.2. Market Share & Forecast
      9.3.2.2.1. By Drug Class
  9.3.3. South Africa Drug Of Abuse Testing Services Market Outlook
    9.3.3.1. Market Size & Forecast
      9.3.3.1.1. By Value
    9.3.3.2. Market Share & Forecast
      9.3.3.2.1. By Drug Class

10. SOUTH AMERICA DRUG OF ABUSE TESTING SERVICES MARKET OUTLOOK

10.1. Market Size & Forecast
  10.1.1. By Value
10.2. Market Share & Forecast
  10.2.1. By Drug Class
  10.2.2. By Country
10.3. South America: Country Analysis
  10.3.1. Brazil Drug Of Abuse Testing Services Market Outlook
    10.3.1.1. Market Size & Forecast
      10.3.1.1.1. By Value
    10.3.1.2. Market Share & Forecast
      10.3.1.2.1. By Drug Class
  10.3.2. Colombia Drug Of Abuse Testing Services Market Outlook
    10.3.2.1. Market Size & Forecast
      10.3.2.1.1. By Value
    10.3.2.2. Market Share & Forecast
      10.3.2.2.1. By Drug Class
  10.3.3. Argentina Drug Of Abuse Testing Services Market Outlook
    10.3.3.1. Market Size & Forecast
      10.3.3.1.1. By Value
    10.3.3.2. Market Share & Forecast
      10.3.3.2.1. By Drug Class

11. MARKET DYNAMICS

11.1. Drivers
11.2. Challenges

12. MARKET TRENDS & DEVELOPMENTS

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. GLOBAL DRUG OF ABUSE TESTING SERVICES MARKET: SWOT ANALYSIS

14. PORTER'S FIVE FORCES ANALYSIS

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. COMPETITIVE LANDSCAPE

15.1. Quest Diagnostics
  15.1.1. Business Overview
  15.1.2. Products & Services
  15.1.3. Recent Developments
  15.1.4. Key Personnel
  15.1.5. SWOT Analysis
15.2. LabCorp
15.3. Abbott
15.4. Thermo Fisher Scientific
15.5. Siemens Healthineers
15.6. OraSure Technologies
15.7. Huer Diagnostics
15.8. Kindred Biosciences
15.9. Eurofins Scientific
15.10. BioReference Laboratories

16. STRATEGIC RECOMMENDATIONS

17. ABOUT US & DISCLAIMER